High Serum sCD40L Levels During the First Week of Malignant Middle Cerebral Artery Infarction and Mortality

Abstract Background There has been found higher circulating soluble cluster of differentiation 40 ligand (sCD40L) levels at admission of an ischemic stroke in non-survivor than in survivor patients. Thus, the objectives of this study were to determine whether serum sCD40L levels during the first week of a severe malignant middle cerebral artery infarction (MMCAI) are higher in non-survivor than in survivor patients and whether could be used as biomarker of mortality prediction. Methods This multicenter study included patients with severe MMCAI (defined as Glasgow Coma Scale Results Non-survivor (n=34) showed higher sCD40L levels on day 1 (p Conclusions The findings that non-survivor showed higher serum sCD40L levels during the first week of MMCAI than survivors, and that serum sCD40L levels during the first week of MMCAI could be used as mortality predictor biomarker are two novel findings.